drug
torsemide
Marketedupdated 3mo agoby CorePharma LLC
Approvedcommunity read0 votes
indications
investigational
Hypertension
all catalysts(0)
nothing on the calendar yet
Trials studying torsemide
- phase1Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
- phase2Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
- phase4Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
- phase3Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
- phase3A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
- phase3A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
- phase3Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects
- phase4A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 6, 2033
~7.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Oct 6, 2033formulationUS 10154963
- Oct 6, 2033formulationUS 10154963
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that